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Abstract
Immunotherapy is widely used in the treatment of different cancer types, including 
metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial 
cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial 
activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). 
This editorial focus on the possible mechanisms of ACC immunoevasion and suggests 
strategies to overcome the intrinsic immunotherapy resistance of this disease.
Adrenocortical carcinoma (ACC) is a rare endocrine 
neoplasia characterized by an overall dismal prognosis and 
its clinical manifestations are the consequence of either 
steroid excess or tumor mass progression (1). Surgery is the 
mainstay of therapy. For patients with locally advanced or 
metastatic ACC, not amenable to surgery, mitotane and 
cytotoxic chemotherapy (with etoposide, doxorubicin 
and cisplatin – EDP scheme) are the systemic treatments 
currently in use (2).
No effective second-line therapies are available for 
patients with disease progression to EDP and mitotane (3).
The concept that immune system modulation can 
lead to a long-lasting control of tumor growth is well 
known since decades. However, the interest for cancer 
immunotherapies used in the past, such as interleukin-2, 
was modest due to the ability of tumor cells to avoid 
elimination by the immune system (4).
Over the past two decades, a tremendous progress has 
been made in the understanding of how cancer evades 
the immune system, as well as the ways to counteract 
the cancer immune evasion (5).
Basic science uncovered the pathways restraining 
antitumor immunity and drugs targeting immune 
checkpoint molecules, such as cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), programmed death 1 (PD-1) and 
programmed death ligand 1 (PD-L1), are important 
therapeutic breakthroughs in medical oncology (5). These 
drugs have demonstrated to be efficacious (and obtained 
the US Food and Drug Administration – FDA – approval) 
against a broad spectrum of cancer types including 
metastatic melanoma, non-small-cell lung cancer, renal 
cell carcinoma and urothelial cancer (6, 7, 8, 9).
There is a rational in the use of immunotherapy also in 
ACC. This tumor, in fact, has an intermediate mutational 
load (8.9% of cells with a number of non-synonymous 
mutations more than 192) (10), that is a surrogate 
indicator of immune responsiveness (11). In addition, 
Melan-A/MART1, one of the most immunogenic antigen 
in melanoma (12), is widely expressed in adrenocortical 
tumors, being one of the markers used to identify lesions 
with adrenocortical origin (13).
JAVELIN study is a phase 1, open-label, dose-escalation 
trial of avelumab, antibody targeting PD-L1, with consecutive 
parallel group expansion in subjects with selected tumor 
indications (ClinicalTrials.gov Identifier: NCT01772004). 
One of the study cohort included ACC patients previously 
treated with platinum-based chemotherapy. They received 
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unacceptable toxicity or withdrawal. Prior and ongoing 
treatment with mitotane was permitted. Considering 50 
patients, this represents the largest prospective study testing 
immunotherapy in ACC. The recently published results 
(14), showed a confirmed overall response rate (ORR) of 
6.0% (95% confidence interval (CI): 1.3–16.5), a median 
progression-free survival (PFS) of 2.6  months (95% CI 
1.4–4.0) and a median overall survival (OS) of 10.6 months 
(95% CI 7.4–not estimable).
These results were similar to the ORR of 4.9%, PFS of 
3 months and OS of 10 months obtained by a standard 
second-line therapy with gemcitabine and metronomic 
capecitabine (15), employed in a real world practice 
setting in a retrospective multicenter study (16).
So, why immunotherapy can lead to such modest 
results in ACC patients? Tumor intrinsic and/or systemic 
factors could impair immunotherapy activity in this 
disease (Fig. 1).
First of all, PDL-1 expression, a well-known predictor 
of activity and better survival for cancer patients treated 
with immune checkpoint inhibitors (17), was found in a 
minority of ACC neoplasms (18). Moreover, the majority 
of ACC patients has a hormone-secreting disease and 
glucocorticoids are known to exert an immunosuppressive 
effect (19). Thus, both endogenous glucocorticoid 
levels, due to tumor secretion, and glucocorticoid 
supplementation in patients treated with mitotane have 
the potential to impair immunotherapy efficacy in ACC 
patients (20).
More importantly, responsiveness to checkpoint 
blockade immunotherapy requires the presence of CD8+ 
T cells within the local tumor microenvironment. As 
recently pointed out (21), molecular analyses revealed 
that the activation of specific oncogenic pathways in 
tumor cells leads to an altered production of CD8+ 
infiltrate thus impairing the local antitumor immune 
response. At least five pathways have been identified 
that may impair CD8+ action: (1) activation of WNT-
β‐catenin pathway or (2) activation of MYC signaling, (3) 
loss of liver kinase B1 (LKB1) signaling, (4) loss of PTEN 
protein function and (5) TP53 mutations. Two of these 
pathways, namely WNT-B-catenin amplification and 
TP53 mutation, are involved in the pathogenesis of ACC. 
Upregulation of β-catenin reduces production by different 
chemokines, such as CC-chemokine ligand 4 (CCL4), 
leading to a defective recruitment of BATF3 dendritic 
cells (basic leucine zipper transcriptional factor ATF-
like 3 lineage) and the lack of effector T cell infiltration. 
Similarly, TP53‐mutated tumor cells lack production of 
key chemokines required for the recruitment of natural 
killer cells and T cells, which results in effector T cell 
exclusion from the tumor infiltration (21, 22, 23).
All these potential mechanisms of immunoresistance 
are summarized in Fig. 1.
Figure 1
Mechanisms of ACC immunoresistance. The upregulation of β-catenin reduces production of different chemokines (such as CCL4, BATF Dcs, CXCL10) 
leading to the lack of T cell priming and the consequent recruitment of effector T cells in the tumor. TP53‐mutated tumor cells lack production of key 
chemokines required for the recruitment of natural killer cells and T cells, which results in exclusion of effector T cell from the tumor infiltration. Low 
PD-L1 expression and increased production of steroids can impair tumor immunogenicity. BATF DC, basic leucine zipper transcriptional factor ATF-like 3 
lineage dendritic cells; CCL, CC-chemokine ligand; CXCL, CXC-chemokine ligand; PD-L1, programmed cell death 1 ligand 1.
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On these grounds, an effective strategy to overcome 
the immune evasion in ACC could be the administration 
of immune checkpoint inhibitors in association with 
drugs targeting the WNT-beta catenin and p53 pathways.
Both active inhibitors of Wnt secretion and Wnt/
receptor interactions are being tested in early phase 
trials (24). Approaches aimed at upregulating p53 are 
under exploration, including gene therapy that uses 
viruses to deliver p53 to cancer cells, synthetic peptides 
that stabilize WT p53 and small molecules that target 
key signaling interactions involving mutant p53 (25). 
Moreover, β-catenin-induced immunotherapy resistance 
could be reversed by injection of mature dendritic cells 
into β-catenin-positive tumors (26).
None of these new drugs and treatment strategies, 
however, will be available soon in the management 
of ACC.
So what kind of immunotherapy trials can be 
currently designed? Immune checkpoint inhibitors can 
be tested in selected ACC patients, such as those with 
alterations in the mismatch repair (MMR) pathway that 
leads to high levels of microsatellite instability (MSI-H). 
Pertinently, MSI-H constitutes the molecular etiology 
of Lynch syndrome, an autosomal dominant genetic 
condition that has a high risk of colon cancer as well as 
other cancers including ACC (27). The damage to the 
MMR process leads to additive mutations throughout the 
genome, leading to a ‘hypermutator’ phenotype that is 
a predisposing condition of response to immunotherapy. 
Moreover, there is an increasing interest in combining 
chemotherapy, radiotherapy or molecular target 
therapies with immunotherapy (28, 29) and of course 
also agents inhibiting steroid synthesis may have a role 
in pretreatment of ACCs with cortisol excess aiming 
to avoid interference with the efficacy of following 
immunotherapy. In a recently published prospective 
clinical trial, the addition of a monoclonal anti-PD-L1 
antibody atezolizumab to chemotherapy in the first-line 
treatment of advanced/metastatic small-cell lung cancer 
resulted in significantly longer OS than chemotherapy 
alone (30). On the basis of these results, the efficacy of 
the standard EDP-M can be improved by the combination 
with a checkpoint inhibitor.
In conclusion, Paul Carpenter published in 1993 
an editorial entitled ‘Mitotane failure in adrenocortical 
cancer: where next?’ as a comment of some negative 
results obtained with this drug at that time (31). In the 
subsequent years, we have learned how to better use this 
drug with the introduction of serum levels monitoring 
and the identification of the so-called ‘therapeutic range’ 
to be attained (32, 33). Mitotane is currently the most 
important drug in this disease, and it is recommended 
and widely used also in adjuvant setting (34). We hope 
that the present editorial with a similar title to that of Paul 
Carpenter could be auspicious for a future demonstration 
of efficacy of immunotherapy in ACC.
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